Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 6/20 | 0.50 |
| ▸ | CNR1 | P21554 | 2/20 | 0.48 |
| ▸ | CNR2 | P34972 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | HTR1D | P28221 | 2/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.47 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.46 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14686106 | 0.95 | HTR1B (0.51) | HTR1BCNR1CNR2CYP2C9HTR1D | |
| SCHEMBL14686126 | 0.91 | HTR1B (0.48) | HTR1BCNR1CNR2HTR1DMCHR1 | |
| SCHEMBL8678740 | 0.84 | ESR1 (0.47) | HTR1BTLR8SLC6A4 | |
| SCHEMBL249286 | 0.83 | KCNA3 (0.55) | HTR1BCNR1CNR2CYP2C9HTR1D | |
| SCHEMBL24168814 | 0.82 | MCHR1 (0.54) | HTR1BCNR1CNR2CYP2C9HTR1D | |
| SCHEMBL30539214 | 0.82 | MCHR1 (0.54) | HTR1BCNR1CNR2CYP2C9HTR1D | |
| SCHEMBL9643551 | 0.81 | CNR1 (0.47) | HTR1BCNR1CNR2CYP2C9HTR1D | |
| SCHEMBL15565685 | 0.81 | HTR1B (0.49) | HTR1BCNR1CNR2CYP2C9HTR1D | |
| SCHEMBL250503 | 0.80 | HTR1B (0.71) | HTR1BCNR1CNR2CYP2C9HTR1D | |
| SCHEMBL8214320 | 0.80 | ALDH1A1 (0.55) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1339663-B1 | NAPHTHALENE DERIVATIVES | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| EP-2338886-A2 | Naphthalene derivatives | Novartis AG (CH) | 2011-06-29 | — | — | EP | disclosed |
| US-7045533-B2 | Such as naphthalen-1-yl-(4-pentyloxy-naphthalen-1-yl)-mehtane for treatment/prevention of diseases/conditions associated with cannobinoid receptor activation such as chronic pain, osteo- and rheumatoid arthritis, teno-synovitis and gout | NOVARTIS AG (CH) | 2006-05-16 | — | — | US | disclosed |
| CN-1224598-C | Naphthalene derivatives | NOVARTIS AG (CH) | 2005-10-26 | — | — | CN | disclosed |
| US-20040053890-A1 | Naphthalene derivatives | NOVARTIS AG (CH) | 2004-03-18 | — | — | US | disclosed |
| CN-1476424-A | Naphthalene derivatives | ��˹��ŵ�� | 2004-02-18 | — | — | CN | disclosed |
| EP-1339663-A2 | NAPHTHALENE DERIVATIVES | Novartis AG (CH) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002042248-A2 | NAPHTHALENE DERIVATIVES | NOVARTIS AG (CH) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053890-A1 | Naphthalene derivatives | CYP1A1, SULT1E1, CYP2F1 | HTR1B 914/4885CNR1 35/4885CNR2 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.